Ownership history in UBS Group AG · 22 quarters on record
This page tracks every 13F SEC filing in which UBS Group AG reported a position in XTL BIOPHARMACEUTICALS LTD (XTLB). Data includes quarterly share count, position size as % of portfolio, estimated market value, and end-of-quarter stock price — sourced directly from SEC EDGAR 13F filings.
| Quarter | Action | Shares | Change | Chg % | % of Fund | Mkt Value | Price (EOQ) |
|---|---|---|---|---|---|---|---|
| 2025 Q3 | REDUCED | 763 | -573 | -42.9% | 0.00% | $893 | $1.17 |
| 2025 Q2 | REDUCED | 1,336 | -5,618 | -80.8% | 0.00% | $2K | $1.14 |
| 2024 Q1 | ADDED | 6,954 | +6,900 | +12777.8% | 0.00% | $20K | $2.81 |
| 2023 Q4 | REDUCED | 54 | -66 | -55.0% | 0.00% | $55 | $1.01 |
| 2023 Q3 | REDUCED | 120 | -180 | -60.0% | 0.00% | $108 | $0.90 |
| 2022 Q4 | REDUCED | 300 | -512 | -63.1% | 0.00% | $363 | $1.21 |
| 2022 Q1 | REDUCED | 812 | -2,086 | -72.0% | 0.00% | $2K | $2.37 |
| 2021 Q3 | REDUCED | 2,898 | -626 | -17.8% | 0.00% | $13K | $4.38 |
| 2021 Q1 | ADDED | 3,524 | +2,488 | +240.2% | 0.00% | $12K | $3.33 |
| 2020 Q3 | REDUCED | 1,036 | -188 | -15.4% | 0.00% | $2K | $1.90 |
As of 2025 Q4 — sorted by position size